Alnylam Pharmaceuticals Inc (NAS:ALNY)
$ 264.95 -2.035 (-0.76%) Market Cap: 35.37 Bil Enterprise Value: 33.64 Bil PE Ratio: 72.39 PB Ratio: 32.87 GF Score: 74/100

Alnylam Pharmaceuticals Inc at Bank of America Global Healthcare Conference Transcript

May 13, 2026 / 05:40PM GMT
Release Date Price: $291.48 (-0.19%)
Tazeen Ahmad
Bofa Merrill Lynch Asset Holdings Inc - Analyst

The healthcare conference, good morning. I'm Tazeen Ahmad. I'm one of the senior biotech analysts at the bank. It's my pleasure to have our next presenting company with us, Alnylam Pharmaceuticals. Sitting up here on stage with me is Jeff Poulton, who is, of course, Chief Financial Officer. Jeff, welcome back to Las Vegas. Thanks for making the trip.

Jeffrey Poulton
Alnylam Pharmaceuticals Inc - Chief Financial Officer, Executive Vice President

No, I always make the trip to Vegas. I'm always here for this one. So I appreciate the invite.

Questions & Answers

Tazeen Ahmad
Bofa Merrill Lynch Asset Holdings Inc - Analyst

Yeah. We have to continue the tradition. So maybe we can start off with a quick overview of the company in case anyone in the room isn't as familiar with Alnylam and its platform.

Jeffrey Poulton
Alnylam Pharmaceuticals Inc - Chief Financial Officer, Executive Vice President

Yeah. I

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot